About HATIP

A regular electronic newsletter for health care workers and community-based organisations on HIV treatment in resource-limited settings.

Its publication is supported by the UK government's Department for International Development (DfID), the Diana, Princess of Wales Memorial Fund and the Stop TB Department of the World Health Organization.

Other supporters include Positive Action GlaxoSmithKline (founding sponsor); Abbott Fund; Abbott Molecular; Cavidi; Elton John AIDS Foundation; Merck & Co., Inc.; Pfizer Ltd; F Hoffmann La Roche; Schering Plough; and Tibotec, a division of Janssen Cilag.

latest aidsmap news

• Study explores verbal and non-verbal communication in unprotected sex between men
• IL-2 provides quick ‘AIDS rescue’, but effect does not always last
• Once-a-day etravirine should work as first-line treatment
• Second-line combinations fail twice as often as first-line ones in the first year
• If you can't switch, better to stay on failing treatment than stop it, studies show
• Non-nucleoside resistance is efficiently transmitted within infection ‘clusters’
• One in five Kenyan patients suffers major interactions with HIV drugs
• HIV treatment safe and effective in South African patients with hepatitis B co-infection, but co-infection frequent
• South African resistance survey confirms that clade C is more likely to develop multi-drug resistance mutation
• Treatment breaks set for a come-back?